Wall Street Wraps a Strong Quarter as Lilly Obesity Data Rolls In
Stocks are finishing the quarter on a high note while Eli Lilly's latest obesity drug trial results send mixed signals to investors.
Wall Street is heading into the finish line of a notably strong quarter, giving investors plenty to feel good about as they close out their portfolios for the period. Major indexes have held up well, and the mood on trading floors leans optimistic heading into the final hour of the session.
Meanwhile, Eli Lilly is back in the spotlight with new clinical trial data for its obesity drug — and the results are, well, a little bit of everything. Mixed data like this can be tricky to interpret: some numbers point in a promising direction while others leave analysts wanting more. For a company that's been one of the hottest names in the weight-loss drug race, anything short of a clean sweep tends to rattle nerves.
Read more UK Bank Stocks Slide as 30-Year Gilt Yields Hit 1998 High →
The obesity drug market is fiercely competitive right now, with Lilly and rivals jockeying for position in what analysts widely consider one of the biggest pharmaceutical growth opportunities in decades. Mixed trial results don't necessarily spell trouble, but they do add a layer of uncertainty to a stock that many retail and institutional investors have ridden aggressively higher.
For everyday investors trying to make sense of the afternoon action, CNBC's Investing Club drops its "Homestretch" update each weekday — a quick, actionable briefing timed specifically for that critical last hour of trading when volatility can spike and big moves happen. Think of it as your cheat sheet before the closing bell.
Continue reading at CNBC
